Diabetic Gastroparesis - Pipeline Review, H2 2016

Date: August 31, 2016
Pages: 63
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: D2659CAC27DEN
Leaflet:

Download PDF Leaflet

Diabetic Gastroparesis - Pipeline Review, H2 2016

SUMMARY

Global Markets Direct’s, ‘Diabetic Gastroparesis - Pipeline Review, H2 2016’, provides an overview of the Diabetic Gastroparesis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Diabetic Gastroparesis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Gastroparesis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Diabetic Gastroparesis
  • The report reviews pipeline therapeutics for Diabetic Gastroparesis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Diabetic Gastroparesis therapeutics and enlists all their major and minor projects
  • The report assesses Diabetic Gastroparesis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Diabetic Gastroparesis
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Diabetic Gastroparesis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Diabetic Gastroparesis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Diabetic Gastroparesis Overview
Therapeutics Development
Pipeline Products for Diabetic Gastroparesis - Overview
Pipeline Products for Diabetic Gastroparesis - Comparative Analysis
Diabetic Gastroparesis - Therapeutics under Development by Companies
Diabetic Gastroparesis - Therapeutics under Investigation by Universities/Institutes
Diabetic Gastroparesis - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Diabetic Gastroparesis - Products under Development by Companies
Diabetic Gastroparesis - Products under Investigation by Universities/Institutes
Diabetic Gastroparesis - Companies Involved in Therapeutics Development
Cempra Inc
Evoke Pharma, Inc.
GlaxoSmithKline Plc
Motus Therapeutics Inc
Shire Plc
Theravance Biopharma, Inc.
Diabetic Gastroparesis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
camicinal - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CEM-031 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ETX-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ETX-301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
metoclopramide hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
prucalopride succinate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
relamorelin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate nNOS for Diabetic Gastroparesis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
velusetrag hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Diabetic Gastroparesis - Dormant Projects
Diabetic Gastroparesis - Discontinued Products
Diabetic Gastroparesis - Product Development Milestones
Featured News & Press Releases
Jul 26, 2016: Evoke Pharma Receives Conditional FDA Acceptance of Proposed Brand Name for EVK-001
Jul 18, 2016: Evoke Pharma Reports Topline Results from EVK-001 Phase 3 Clinical Trial
Jul 07, 2016: Evoke Advances Commercial Preparations for EVK-001 with inVentiv Agreement
Jun 01, 2016: Evoke Completes Phase 3 Clinical Trial of EVK-001 in Women with Symptoms Associated with Diabetic Gastroparesis
May 24, 2016: Evoke Pharma Presents Data from Successful Thorough ECG (TQT) Study of EVK-001 at Digestive Disease Week 2016
May 19, 2016: Evoke Enters Exclusive Commercial Supply Agreement for Active Pharmaceutical Ingredient in EVK-001
May 03, 2016: Evoke Announces Timing of Phase 3 Results from its Recently Fully Enrolled Pivotal Clinical Trial of EVK-001
Apr 25, 2016: Evoke Successfully Completes Phase 3 Clinical Trial Enrollment of EVK-001 in Women with Symptoms Associated with Diabetic Gastroparesis
Apr 04, 2016: Motus Completes Enrollment of Phase 2b Clinical Trial of Relamorelin for Diabetic Gastroparesis
Mar 03, 2016: Evoke Accelerates New Drug Application Process by Engaging Regulatory Experts
Mar 01, 2016: Evoke Nears Completion of Phase 3 Clinical Trial Enrollment and Secures Extension to Credit Facility
Feb 17, 2016: Evoke Pharma to Present Results From Successful Thorough ECG (TQT) Study of EVK-001 at Digestive Disease Week 2016
Sep 28, 2015: Evoke Reaches Study Enrollment Milestone Associated With Credit Facility
Aug 18, 2015: Evoke Receives Favorable Response From U.S. Food and Drug Administration Regarding Pediatric Study Plan for EVK-001
Jun 24, 2015: Evoke Pharma Announces Publication of Clinical Data Demonstrating EVK-001 Significantly Improves Symptoms in Women With Diabetic Gastroparesis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Diabetic Gastroparesis, H2 2016
Number of Products under Development for Diabetic Gastroparesis - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Diabetic Gastroparesis - Pipeline by Cempra Inc, H2 2016
Diabetic Gastroparesis - Pipeline by Evoke Pharma, Inc., H2 2016
Diabetic Gastroparesis - Pipeline by GlaxoSmithKline Plc, H2 2016
Diabetic Gastroparesis - Pipeline by Motus Therapeutics Inc, H2 2016
Diabetic Gastroparesis - Pipeline by Shire Plc, H2 2016
Diabetic Gastroparesis - Pipeline by Theravance Biopharma, Inc., H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Diabetic Gastroparesis - Dormant Projects, H2 2016
Diabetic Gastroparesis - Discontinued Products, H2 2016

LIST OF FIGURES

Number of Products under Development for Diabetic Gastroparesis, H2 2016
Number of Products under Development for Diabetic Gastroparesis - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Targets, H2 2016
Number of Products by Stage and Targets, H2 2016
Number of Products by Mechanism of Actions, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

COMPANIES MENTIONED

Cempra Inc
Evoke Pharma, Inc.
GlaxoSmithKline Plc
Motus Therapeutics Inc
Shire Plc
Theravance Biopharma, Inc.
Skip to top


Gastroparesis - Pipeline Review, H1 2015 US$ 1,600.00 Feb, 2015 · 37 pages
Diabetic Gastroparesis - Pipeline Insights, 2016 US$ 1,000.00 Nov, 2016 · 60 pages
Seek - Product Pipeline Review - 2014 US$ 1,125.00 Oct, 2014 · 42 pages

Ask Your Question

Diabetic Gastroparesis - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: